Ken Griffin Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $1.02 Million - $1.08 Million	-25,000 Reduced 29.98%	58,400 $2.47 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $1.22 Million - $2.55 Million	60,100 Added 257.94%	83,400 $3.54 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $514,604 - $810,514	-25,400 Reduced 52.16%	23,300 $508,000
Q2 2023 Aug 14, 2023	BUY	$23.9 - $35.38 $592,720 - $877,424	24,800 Added 103.77%	48,700 $1.55 Million
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $285,250 - $441,500	-12,500 Reduced 34.34%	23,900 $582,000

Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $98,865 - $124,644	3,900 Added 12.0%	36,400 $1.15 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $280,500 - $455,620	11,000 Added 51.16%	32,500 $918,000

227

150M

939K

961K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Market Cap $6.37B
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.